EGFR and non-small cell lung carcinoma: Jia et al. (55) tested the in vitro and in vivo efficacy of EAI045 in genetically engineered Ba/F3 cells and a mouse model, and only EAI045 in combination with cetuximab was effective for NSCLC driven by EGFR L858R/T790M and L858R/T790M/C797S.